Published in Ann Neurol on March 01, 2006
Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke (2009) 6.79
Can animal models of disease reliably inform human studies? PLoS Med (2010) 6.27
Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature (2012) 4.04
Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med (2009) 3.35
Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology (2008) 3.04
Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol (2010) 2.72
Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol (2013) 2.70
Anti-aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron (2011) 2.67
Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci (2010) 2.40
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results. Stroke (2010) 2.29
Translating animal research into clinical benefit. BMJ (2007) 2.25
Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med (2013) 1.92
Tsc1 (hamartin) confers neuroprotection against ischemia by inducing autophagy. Nat Med (2013) 1.89
Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab (2010) 1.89
Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? J Cereb Blood Flow Metab (2010) 1.85
High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol (2013) 1.75
Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke (2008) 1.72
The neurovascular unit and combination treatment strategies for stroke. Trends Pharmacol Sci (2012) 1.66
Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke (2008) 1.64
Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One (2010) 1.63
Evolution and translation of research findings: from bench to where? PLoS Clin Trials (2006) 1.60
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Reprint: Good laboratory practice: preventing introduction of bias at the bench. J Cereb Blood Flow Metab (2008) 1.47
A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab (2009) 1.45
Cocktail treatment, a promising strategy to treat acute cerebral ischemic stroke? Med Gas Res (2016) 1.42
Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab (2010) 1.42
Degeneration and repair in central nervous system disease. Nat Med (2010) 1.42
Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem (2011) 1.41
Preclinical stroke research--advantages and disadvantages of the most common rodent models of focal ischaemia. Br J Pharmacol (2011) 1.39
Cell based therapies for ischemic stroke: from basic science to bedside. Prog Neurobiol (2013) 1.39
Systematic survey of the design, statistical analysis, and reporting of studies published in the 2008 volume of the Journal of Cerebral Blood Flow and Metabolism. J Cereb Blood Flow Metab (2010) 1.35
A concerted appeal for international cooperation in preclinical stroke research. Stroke (2013) 1.32
Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br J Pharmacol (2007) 1.31
Prehospital use of magnesium sulfate as neuroprotection in acute stroke. N Engl J Med (2015) 1.29
Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One (2011) 1.28
Hypothermia for acute brain injury--mechanisms and practical aspects. Nat Rev Neurol (2012) 1.28
Nonconvulsive seizures after subarachnoid hemorrhage: Multimodal detection and outcomes. Ann Neurol (2013) 1.26
Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets (2008) 1.24
Sex differences in stroke. Cerebrovasc Dis (2008) 1.24
A novel family of negative and positive allosteric modulators of NMDA receptors. J Pharmacol Exp Ther (2010) 1.22
A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib. Elife (2015) 1.20
Blood-brain barrier breakdown after embolic stroke in rats occurs without ultrastructural evidence for disrupting tight junctions. PLoS One (2013) 1.20
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab (2008) 1.17
Bringing rigour to translational medicine. Nat Rev Neurol (2013) 1.16
Vascular plasticity in cerebrovascular disorders. J Cereb Blood Flow Metab (2011) 1.15
Neuroprotection in acute ischemic stroke--current status. J Cell Mol Med (2010) 1.15
Ischemic stroke in the elderly: an overview of evidence. Nat Rev Neurol (2010) 1.15
Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch Toxicol (2013) 1.14
Attenuated inflammatory response in aged mice brains following stroke. PLoS One (2011) 1.14
Docosahexaenoic acid signaling modulates cell survival in experimental ischemic stroke penumbra and initiates long-term repair in young and aged rats. PLoS One (2012) 1.14
Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke. Neurology (2014) 1.13
A grading system to evaluate objectively the strength of pre-clinical data of acute neuroprotective therapies for clinical translation in spinal cord injury. J Neurotrauma (2010) 1.13
The role of microglia and myeloid immune cells in acute cerebral ischemia. Front Cell Neurosci (2015) 1.12
Cerebral blood flow alteration in neuroprotection following cerebral ischaemia. J Physiol (2011) 1.11
Systematic reviews and meta-analysis of preclinical studies: why perform them and how to appraise them critically. J Cereb Blood Flow Metab (2014) 1.11
Rodent models of focal cerebral ischemia: procedural pitfalls and translational problems. Exp Transl Stroke Med (2009) 1.11
Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol (2014) 1.10
Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent. Future Neurol (2009) 1.09
Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab (2010) 1.08
Dealing with publication bias in translational stroke research. J Exp Stroke Transl Med (2009) 1.08
The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. Int J Mol Sci (2013) 1.07
Role of Nogo-A in neuronal survival in the reperfused ischemic brain. J Cereb Blood Flow Metab (2010) 1.06
Nonhuman primate models of stroke for translational neuroprotection research. Neurotherapeutics (2012) 1.05
Methodology of the Field Administration of Stroke Therapy - Magnesium (FAST-MAG) phase 3 trial: Part 1 - rationale and general methods. Int J Stroke (2014) 1.05
Reporting of observational studies. BMJ (2007) 1.04
Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci (2012) 1.04
Pathophysiologic cascades in ischemic stroke. Int J Stroke (2012) 1.03
Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med (2011) 1.03
Neuroprotection after stroke by targeting NOX4 as a source of oxidative stress. Antioxid Redox Signal (2012) 1.03
Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr Pharm Des (2013) 1.03
Stroke-induced brain parenchymal injury drives blood-brain barrier early leakage kinetics: a combined in vivo/in vitro study. J Cereb Blood Flow Metab (2013) 1.02
Experimental intracerebral hemorrhage: avoiding pitfalls in translational research. J Cereb Blood Flow Metab (2011) 1.02
Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing. J Cereb Blood Flow Metab (2010) 1.02
Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochem Int (2012) 1.02
Systematic reviews of animal models: methodology versus epistemology. Int J Med Sci (2013) 1.01
Granulocyte-colony stimulating factor for stroke treatment: mechanisms of action and efficacy in preclinical studies. Exp Transl Stroke Med (2009) 1.01
Ischemic preconditioning alters the epigenetic profile of the brain from ischemic intolerance to ischemic tolerance. Neurotherapeutics (2013) 1.01
Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke. BMC Neurosci (2009) 1.00
The science of cerebral ischemia and the quest for neuroprotection: navigating past failure to future success. J Neurosurg (2013) 1.00
New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics. Evid Based Complement Alternat Med (2013) 1.00
Systematic identification of gene activities promoting hypoxic death. Genetics (2008) 1.00
Glyburide is associated with attenuated vasogenic edema in stroke patients. Neurocrit Care (2014) 1.00
Animal models and conserved processes. Theor Biol Med Model (2012) 0.99
Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid. Neuropharmacology (2011) 0.99
A systematic review and meta-analysis of buyang huanwu decoction in animal model of focal cerebral ischemia. Evid Based Complement Alternat Med (2013) 0.98
Methodological quality of preclinical stroke studies is not required for publication in high-impact journals. J Cereb Blood Flow Metab (2010) 0.98
A critical appraisal of experimental intracerebral hemorrhage research. J Cereb Blood Flow Metab (2012) 0.97
Evaluation of combination therapy in animal models of cerebral ischemia. J Cereb Blood Flow Metab (2012) 0.97
Methodological Rigor in Preclinical Cardiovascular Studies: Targets to Enhance Reproducibility and Promote Research Translation. Circ Res (2017) 0.96
Proton-sensitive cation channels and ion exchangers in ischemic brain injury: new therapeutic targets for stroke? Prog Neurobiol (2014) 0.96
Glutamate mobilizes [Zn2+] through Ca2+ -dependent reactive oxygen species accumulation. J Neurochem (2008) 0.96
Argon inhalation attenuates retinal apoptosis after ischemia/reperfusion injury in a time- and dose-dependent manner in rats. PLoS One (2014) 0.96
Effect of vagus nerve stimulation during transient focal cerebral ischemia on chronic outcome in rats. J Neurosci Res (2012) 0.95
Docosahexaenoic acid neurolipidomics. Prostaglandins Other Lipid Mediat (2009) 0.95
Interleukin-1 and acute brain injury. Front Cell Neurosci (2015) 0.95
Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions. Int J Mol Sci (2013) 0.95
Immune interventions in stroke. Nat Rev Neurol (2015) 0.94
Expressional changes in cerebrovascular receptors after experimental transient forebrain ischemia. PLoS One (2012) 0.94
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet (2010) 12.21
Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med (2015) 12.06
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol (2008) 9.02
Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25
Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke (2009) 6.79
Can animal models of disease reliably inform human studies? PLoS Med (2010) 6.27
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol (2010) 5.58
Pooling of animal experimental data reveals influence of study design and publication bias. Stroke (2004) 4.37
Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke (2008) 3.87
Very early mobilization after stroke fast-tracks return to walking: further results from the phase II AVERT randomized controlled trial. Stroke (2010) 3.43
Good laboratory practice: preventing introduction of bias at the bench. Stroke (2008) 3.27
Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab (2005) 3.20
Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain (2007) 2.94
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol (2012) 2.77
Improving the translational hit of experimental treatments in multiple sclerosis. Mult Scler (2010) 2.73
Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol (2013) 2.70
Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack. N Engl J Med (2012) 2.39
Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol (2002) 2.25
The Avoid Stroke as Soon as Possible (ASAP) general practice stroke audit. Med J Aust (2002) 2.13
Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke. J Stroke Cerebrovasc Dis (2009) 2.12
Therapeutic hypothermia and the risk of infection: a systematic review and meta-analysis. Crit Care Med (2014) 2.05
Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Stroke (2011) 2.03
Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin? Stroke (2004) 2.02
Effective prophylaxis for deep venous thrombosis after stroke: both low-dose anticoagulation and stockings for most cases. Stroke (2004) 2.00
Does abnormal circadian blood pressure pattern really matter in patients with transient ischemic attack or minor stroke? Stroke (2014) 1.98
World Stroke Organization global stroke services guidelines and action plan. Int J Stroke (2014) 1.94
Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis. J Cereb Blood Flow Metab (2010) 1.89
Therapeutic hypothermia for acute ischemic stroke: ready to start large randomized trials? J Cereb Blood Flow Metab (2010) 1.85
Tissue plasminogen activator for ischaemic stroke: highly effective, reasonably safe and grossly underused. Med J Aust (2007) 1.71
Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis. J Cereb Blood Flow Metab (2010) 1.68
Incidence of stroke subtypes in the North East Melbourne Stroke Incidence Study (NEMESIS): differences between men and women. Neuroepidemiology (2008) 1.67
Acute stroke imaging research roadmap. Stroke (2008) 1.66
Dopamine agonists in animal models of Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord (2011) 1.64
Evidence-based care and outcomes of acute stroke managed in hospital specialty units. Med J Aust (2003) 1.61
Risk of ischemic stroke among users of the oral contraceptive pill: The Melbourne Risk Factor Study (MERFS) Group. Stroke (2003) 1.59
Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke (2004) 1.59
Frequent early cardiac complications contribute to worse stroke outcome in atrial fibrillation. Cerebrovasc Dis (2011) 1.53
Cerebral blood flow is the optimal CT perfusion parameter for assessing infarct core. Stroke (2011) 1.52
Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation. Cerebrovasc Dis (2013) 1.52
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke (2014) 1.49
Excessive incidence of stroke in Iran: evidence from the Mashhad Stroke Incidence Study (MSIS), a population-based study of stroke in the Middle East. Stroke (2009) 1.49
Source of microembolic signals in patients with high-grade carotid stenosis. Stroke (2002) 1.48
Acute Stroke Imaging Research Roadmap II. Stroke (2013) 1.47
The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. J Cereb Blood Flow Metab (2011) 1.47
Reprint: Good laboratory practice: preventing introduction of bias at the bench. J Cereb Blood Flow Metab (2008) 1.47
A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab (2009) 1.45
Greater effect of stroke thrombolysis in the presence of arterial obstruction. Ann Neurol (2011) 1.44
Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. Stroke (2005) 1.42
A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke (2012) 1.42
Different strokes for different folks: the rich diversity of animal models of focal cerebral ischemia. J Cereb Blood Flow Metab (2010) 1.42
Mismatch-based delayed thrombolysis: a meta-analysis. Stroke (2009) 1.41
Acute stroke imaging research roadmap. AJNR Am J Neuroradiol (2008) 1.41
Modification of the method of thread manufacture improves stroke induction rate and reduces mortality after thread-occlusion of the middle cerebral artery in young or aged rats. J Neurosci Methods (2006) 1.41
Inflammation following stroke. J Clin Neurosci (2006) 1.40
Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA (2011) 1.40
Surveying the literature from animal experiments: systematic review and meta-analysis are important contributions. BMJ (2005) 1.38
Failure of collateral blood flow is associated with infarct growth in ischemic stroke. J Cereb Blood Flow Metab (2013) 1.36
Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res (2005) 1.35
Systematic survey of the design, statistical analysis, and reporting of studies published in the 2008 volume of the Journal of Cerebral Blood Flow and Metabolism. J Cereb Blood Flow Metab (2010) 1.35
The Virtual International Stroke Trials Archive. Stroke (2007) 1.34
Handicap after stroke: how does it relate to disability, perception of recovery, and stroke subtype?: the north North East Melbourne Stroke Incidence Study (NEMESIS). Stroke (2002) 1.33
Treatment of intracerebral hemorrhage in animal models: meta-analysis. Ann Neurol (2011) 1.26
Selection of thrombolytic therapy beyond 3 h using magnetic resonance imaging. Curr Opin Neurol (2005) 1.25
Assessing reperfusion and recanalization as markers of clinical outcomes after intravenous thrombolysis in the echoplanar imaging thrombolytic evaluation trial (EPITHET). Stroke (2009) 1.23
Animal models of bone cancer pain: systematic review and meta-analyses. Pain (2013) 1.22
How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol (2011) 1.22
Comparison of computed tomography perfusion and magnetic resonance imaging perfusion-diffusion mismatch in ischemic stroke. Stroke (2012) 1.21
Dementia, stroke, and vascular risk factors; a review. Int J Stroke (2012) 1.20
The benefits of intravenous thrombolysis relate to the site of baseline arterial occlusion in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET). Stroke (2010) 1.20
Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice. Br J Pharmacol (2009) 1.18
Stroke thrombolysis: save a minute, save a day. Stroke (2014) 1.17
EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke. Int J Stroke (2014) 1.13
A systematic review and meta-analysis of the efficacy of piracetam and piracetam-like compounds in experimental stroke. Cerebrovasc Dis (2007) 1.13
Greater incidence of both fatal and nonfatal strokes in disadvantaged areas: the Northeast Melbourne Stroke Incidence Study. Stroke (2006) 1.13
Preclinical studies of human disease: time to take methodological quality seriously. J Mol Cell Cardiol (2011) 1.13
Validating imaging biomarkers of cerebral edema in patients with severe ischemic stroke. J Stroke Cerebrovasc Dis (2012) 1.12